A phase 2 study demonstrated that fenebrutinib had higher efficacy than placebo for ACR50 at week 12 in patients with rheumatoid arthritis (RA) with inadequate response to methotrexate or TNF inhibitors. Furthermore, fenebrutinib was similar to adalimumab in methotrexate-refractory patients. The safety profile of fenebrutinib was acceptable.
Fenebrutinib is an orally available highly selective inhibitor of Bruton's tyrosine kinase (BTK) with potential anti-rheumatic activity. Dr Stanley Cohen (Metroplex Clinical Research Center, Dallas, USA) et al. evaluated the efficacy and safety of fenebrutinib compared with placebo and adalimumab, in combination with low-dose methotrexate, in patients with RA .
This multicentre, randomised, double-blind phase 2 trial included patients with moderate-to-severe active RA with an inadequate response to methotrexate or other DMARDs (MTX-IR, cohort 1) or TNF inhibitors (TNF-IR, cohort 2). Patients from the first co...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Filgotinib Is Efficacious and Safe in PsA Next Article
Efficacy and Safety of Bimekizumab in Patients with Active PsA »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.